Faculty

Sadia Z. Shah, M.D.

Clinical Studies

Comparison of Intra-operative Cardio-Pulmonary Bypass Versus Extracorporeal Membrane Oxygenation as an Independent Risk Factor for Development of Primary Graft Dysfunction Post Lung Transplant Jacksonville, Fla.
The purpose of this study is to to determine if Cardiopulmonary Bypass (CPB) is an independent risk factor for development of Primary Graft Dysfunction (PGD) as compared to Extracorporeal Membrane Oxygenation (ECMO) even when adjusted for all other recipient, donor, biologic and operative risk factors.

RECOVER: Phase 2 Randomized, Double-Blind Trial TREating Hospitalized Patients with COVID-19 with Camostat MesilatE, a TMPRSS2 Inhibitor (RECOVER) Jacksonville, Fla., Scottsdale/Phoenix, Ariz.
The primary purpose of this study is to determine if the reduction in TMPRSS2 activity via direct inhibition with Camostat mesilate combined with standard of care (SOC) treatment will increase the proportion of patients alive and free from respiratory failure at Day 28 in SARS-CoV-2 as compared to SOC treatment with placebo.
TRK-250 - A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Inhaled Dose, Safety, Tolerability, and Pharmacokinetic Study of TRK-250 in Subjects With Idiopathic Pulmonary Fibrosis Jacksonville, Fla.
The purpose of this study is to assess the safety and tolerability of single- and multiple-inhaled doses of TRK-250 in subjects with idiopathic pulmonary fibrosis (IPF).

TRK-250 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by selectively suppressing the expression of transforming growth factor-beta 1 (TGF-β1) protein, at the gene expression level.